CANbridge Pharmaceuticals Inc. (HKG: 1228), a specialist in rare diseases based in China, has announced a partnership with Peking Union Medical College Hospital to collaborate on an innovative study spanning drug discovery to clinical translation for rare diseases.
The partnership aims to establish a rare disease innovation development platform focused on addressing scientific challenges in the field, enhancing drug innovation, guiding the development of bio-infrastructure for rare diseases in China, and supporting policy-making related to rare disease security.
CANbridge boasts a diverse product portfolio that includes four approved therapies and ten investigational drugs targeting conditions such as Hunter syndrome, lysosomal storage disorders, complement-mediated diseases, hemophilia A, metabolic disorders, rare cholestatic liver disease, neuromuscular diseases, and glioblastoma. The company is also advancing gene therapies for rare genetic disorders, including Pompe disease, Fabry disease, spinal muscular atrophy (SMA), and other neuromuscular conditions.- Flcube.com
